EGFR and non-small cell lung carcinoma: Molecular characterization of NSCLC tumors has guided therapeutic decisions, making the diagnosis of EGFR mutations a significant starting point, and has highlighted the importance of molecular characterization in guiding diagnosis and therapeutic decisions [95, 96].